Dysfunctional Uterine Bleeding Market is Expected to Grow at a CAGR over 7.20% from 2022 - 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future has a cooked research report on the global dysfunctional uterine bleeding market. 

Market Highlights

According to the American Society for Reproductive Medicine, dysfunctional uterine bleeding is most common during puberty and menopause. It can also can occur at any time in women due to hormonal imbalance. Polycystic ovary syndrome (PCOS), endometriosis, uterine polyps, uterine fibroids, Sexually Transmitted Diseases (STDS) are common causes of dysfunctional uterine bleeding. It can be diagnosed by performing an endometrial biopsy or blood tests.

The rising prevalence of uterine disorders such as endometrial cancer among women, availability of reliable diagnostic tests, and overall demand for new treatment for uterine bleeding drive the market growth.  Increasing number of awareness drives and campaigns regarding cancer among women further influence the market growth.

The Dysfunctional Uterine Bleeding Market is anticipated to reach USD 5,389.76 Million by 2030 at a 7.20 % CAGR during the forecast period 2020-2030.

Taste the market data and market information presented through more than 55 market data tables and figures spread over 101 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Dysfunctional uterine bleeding market research report–Global forecast till 2023.”

Major Players in Dysfunctional uterine bleeding Market:

Some of the key players in the global market are B. Braun Melsungen AG (Germany), Hologic Inc. (U.S.), Karl Storz Gmbh & Co. KG (Germany), Medgyn Products, Inc., Olympus (Japan), Richard Wolf GmbH (Germany), Stryker (U.S.), Xion Medical GmbH (Germany), Cadila Pharmaceuticals Ltd. (India), Torrent Phamraceuticals (India).

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Dysfunctional Uterine Bleeding Market Research Report

Regional Analysis

America is the largest market for dysfunctional uterine bleeding market owing to the rising prevalence of uterine cancer and other uterine disorders among women. According to the American Cancer Institute, about 61,380 new cases of uterine cancer will be diagnosed in 2017 and 8% of the urine cancers are sarcomas.

Europe is the second largest market owing to an increasing demand for diagnosis and treatment measures for uterine cancer, fibroids and other disorder, and increasing emphasis on women healthcare. Additionally, availability of funds for research and development activities accelerates the market growth in the European countries.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing prevalence of menstrual disorders, and sexually transmitted diseases (STI) among women in developing nations. Furthermore, increasing awareness about STI and preventive measures to be taken also influences the market growth.

The Middle East & Africa also show a steady rise in the market owing to increasing focus on women and child health, and need of primary care services in developing regions.

Segmentation

The global dysfunctional uterine bleeding market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of type, market is segmented into ovulatory, and anovulatory.

On the basis of diagnosis, the market is segmented into hysteroscopy, ultrasonography, dilation and curettage, endometrial biopsy, and others.

On the basis of treatment, the market is segmented into pharmacologic treatment, hysterectomy, endometrial ablation, and others. The pharmacologic treatment includes oral contraceptives, estrogen, progestins, desmopressin and others.

On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, pharmaceutical companies, and others.